Literature DB >> 2061441

Successful treatment of adult Henoch-Schönlein purpura with factor XIII concentrate.

A Utani1, M Ohta, A Shinya, S Ohno, H Takakuwa, T Yamamoto, T Suzaki, K Danno.   

Abstract

We report the cases of three adult patients with severe abdominal complications of Henoch-Schönlein purpura who had low activity of factor XIII during the acute phase of the disease. In all three cases, abdominal symptoms and purpura immediately responded to heat-treated, placenta-derived factor XIII concentrate. No adverse effects were experienced. Factor XIII concentrate replacement should be considered as the initial treatment for severe abdominal symptoms in adult Henoch-Schönlein purpura associated with a decreased level of factor XIII activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2061441     DOI: 10.1016/0190-9622(91)70068-d

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  Effect of factor XIII on endothelial barrier function.

Authors:  T Noll; G Wozniak; K McCarson; A Hajimohammad; H J Metzner; J Inserte; W Kummer; F W Hehrlein; H M Piper
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

2.  Regression of Helicobacter pylori-negative duodenal ulcers complicated by Schonlein-Henoch purpura with H. pylori eradication therapy: the first report.

Authors:  Kuang-I Fu; Shinji Yagi; Yumi Mashimo; Kazuhiro Sugitani; Keiji Imamaki; Morifumi Yanagisawa; Suguru Maekawa; Yoshihiro Morimoto; Takahiro Fujimori
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

3.  Carbamazepine-induced thrombocytopenia and leucopenia complicated by Henoch-Schönlein purpura symptoms.

Authors:  K Kaneko; J Igarashi; Y Suzuki; S Niijima; K Ishimoto; K Yabuta
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

4.  Successful Treatment of IgA Vasculitis Complicated with Bowel Perforation and Crescentic Glomerulonephritis by Combination Therapy of Glucocorticoid, Cyclosporine and Factor XIII Replacement.

Authors:  Keiko Koshiba; Sei Muraoka; Toshihiro Nanki; Satoru Komatsumoto
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.